Annaida Technologies is a technology company.
Annaida Technologies has raised $600K across 1 funding round.
Annaida Technologies has raised $600K in total across 1 funding round.
# High-Level Overview
Annaida Technologies is a Swiss biotechnology startup that develops non-invasive technology for analyzing chemical processes in microscopic life forms.[2] Founded in 2019 as an EPFL spinoff, the company has created EmbryoSpin, a groundbreaking device that performs microscopic Nuclear Magnetic Resonance (µNMR) at a scale 10-fold better than existing technologies.[1][3] The company serves multiple markets: assisted reproductive technology (ART) clinics seeking to improve embryo selection for in vitro fertilization, academic research institutions, and pharmaceutical companies conducting toxicology and drug discovery research.[1] Annaida's core value proposition is enabling non-invasive chemical analysis at the cellular scale—allowing researchers and clinicians to understand metabolic fingerprints of embryos and organoids while preserving their full integrity, without relying on toxic labels or invasive biopsies.[4][5]
The company has demonstrated strong early traction, generating its first research product revenues from top-ranked academic laboratories worldwide and closing an oversubscribed Pre-Series A funding round led by HEMEX.[5] This capital injection, combined with support from Horizon Europe's EIC Transition program and Swiss Innovation Project (Innosuisse), positions Annaida to mature its platform into a commercial product targeting the global assisted reproduction market.
# Origin Story
Annaida was founded in 2019 by Marco Grisi and Gora Conley, both physicists trained at EPFL.[2][4] Grisi holds a PhD in microengineering and microelectronics for NMR and serves as CEO and Founder, driving the core technology development and research direction.[2] The founders, despite lacking personal experience with IVF, recognized the potential of micro-NMR technologies after systematically reviewing the literature on applications for chemical analysis of living organisms.[4] They identified embryo screening as a critical gap: existing evaluation techniques were inadequate, and the founders saw an opportunity to translate their physics expertise into a solution addressing a real clinical need.
The company gained early validation through prestigious recognition: it was selected as one of 27 winners in the IMD Startup Competition (2019), survived all stages of the Swiss Venture Kick competition, received an InnoSuisse grant, and ranked in the Top 16 of the 2020 W.A. de Vigier Stiftung award.[4] These early wins established credibility and provided both capital and mentorship as the team moved from concept to commercialization.
# Core Differentiators
# Role in the Broader Tech Landscape
Annaida operates at the intersection of three significant trends: the miniaturization of analytical instrumentation, the growing demand for non-invasive bioanalysis, and the expansion of assisted reproductive technology globally. The company is riding a wave of declining fertility rates across Europe and developed markets, which is driving investment in IVF success optimization.[5] Simultaneously, the life sciences research community is increasingly demanding tools that enable real-time metabolic monitoring without destructive sample preparation—a need Annaida directly addresses.
The timing is particularly favorable: regulatory scrutiny around invasive embryo screening is increasing, patient demand for safer procedures is rising, and pharmaceutical companies are investing heavily in high-throughput drug screening platforms that require non-toxic analytical methods.[4][5] Annaida's technology positions it as a potential category creator in cellular-scale magnetic resonance, potentially influencing how the broader biotech and medtech sectors approach microscopic analysis. Success here could establish a new standard for non-invasive cellular characterization, with applications extending far beyond fertility into regenerative medicine, organoid research, and precision diagnostics.
# Quick Take & Future Outlook
Annaida is well-positioned to become a significant player in assisted reproduction and life sciences instrumentation, contingent on successful commercialization of EmbryoSpin and market adoption by fertility clinics. The company's immediate priorities—scaling R&D, establishing market presence, and maturing the platform into a clinical-grade product—are directly supported by its recent Pre-Series A funding and government backing.[5]
The critical inflection point will be clinical validation: demonstrating that non-invasive µNMR-based embryo screening meaningfully improves IVF success rates and reduces miscarriage risk compared to existing methods. If achieved, this could unlock a substantial global market (millions of women undergoing assisted reproduction annually) and establish Annaida as the de facto standard for cellular-scale magnetic resonance analysis. Longer term, the company's influence may extend beyond fertility into organoid research, personalized medicine, and drug development—transforming how scientists and clinicians understand microscopic life at the chemical level.
Annaida Technologies has raised $600K in total across 1 funding round.
Annaida Technologies's investors include Elbow Beach Capital, Excellis.
Annaida Technologies has raised $600K across 1 funding round. Most recently, it raised $600K Series A in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $600K Series A | Elbow Beach Capital, Excellis |